Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mutation-specific therapy for the long QT syndrome
2020-000250-94Phase 2Terminated
- Sponsor
- Istituto Auxologico Italiano
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of lumacaftor + ivacaftor in congenital long QT syndrome (LQTS), sponsored by Istituto Auxologico Italiano. Primary endpoint: Change in QTc interval after drug treatment. Started Jun 2021; status: terminated.
02
Drugs
lumacaftor + ivacaftor
03
Conditions
congenital long QT syndrome (LQTS)
Beyond the preview
Go deeper on 2020-000250-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000250-94.